Back
to Projects Home
– HDWG Home
Massachusetts Perinatal
Provider HIV Survey, MA Department of Public Health
One of the
great breakthroughs in HIV/AIDS treatment has been the use of the
drug zidovudine (ZDV) to prevent transmission of the HIV virus from
mother to infant. ZDV administered prenatally to the mother, and
to the infant for 6 weeks after birth, has been shown to prevent
transmission in at least 2/3 of cases. A key public health goal
is to ensure access to this treatment for all women who are HIV
and pregnant, through effective counseling, testing and engagement
in care during pregnancy.
The Massachusetts
Department of Public Health has sought to maximize access, by assessing
and tracking physician beliefs and behaviors in this critical area.
Last year, for the third time since the effectiveness of ZDV was
ascertained, the Department engaged HDWG to conduct a statewide
survey of Massachusetts obstetricians and midwives on these topics.
HDWG convened an advisory group to update the survey used in two
previous rounds and then administered the survey to providers statewide.
Analysis of results is currently underway.
Once completed,
this analysis will indicate:
- The extent
to which providers counsel, offer women testing, and test their
pregnant patients for HIV;
- The factors
(including provider-related factors, caseload-related factors,
and environmental factors) which promote or impede effective HIV
care for women;
- Provider
attitudes and perceptions associated with effective HIV care for
women.
This information
will permit the state and other interested parties to target providers
in need of training, technical assistance or resources to promote
universal access to HIV care for pregnant women.
Project Staff:
Deborah Allen, Irene Shui, Sarah
Du Rei, Steve Finch.
|
|